Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country

NCT05644067 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Malaria

Interventions

BIOLOGICAL: SumayaVac-1(SUM-101)
BIOLOGICAL: Verorab

Sponsor

Swiss Tropical & Public Health Institute

Collaborators

[object Object]
[object Object]